

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7599188

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECOND LIEN PATENT SECURITY AGREEMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	INSMED INCORPORATED	10/19/2022
RECEIVING PARTY DATA		
Name:	ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP	
Street Address:	601 LEXINGTON AVENUE	
Internal Address:	54TH FLOOR	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10022	
PROPERTY NUMBERS Total: 113		
Property Type	Number	
Application Number:	10522344	
Application Number:	10533430	
Application Number:	10538515	
Application Number:	10696389	
Application Number:	10778636	
Application Number:	10810098	
Application Number:	10866086	
Application Number:	11185448	
Application Number:	11311633	
Application Number:	11634343	
Application Number:	12250412	
Application Number:	12748756	
Application Number:	13042980	
Application Number:	13144553	
Application Number:	13480246	
Application Number:	13527213	
Application Number:	13566707	
Application Number:	13664181	
Application Number:	13666420	

PATENT

Property Type	Number
Application Number:	13675559
Application Number:	13675587
Application Number:	13899457
Application Number:	14123634
Application Number:	14319018
Application Number:	14523538
Application Number:	14601371
Application Number:	14641104
Application Number:	14713926
Application Number:	14791979
Application Number:	14809127
Application Number:	14809128
Application Number:	14907746
Application Number:	14987508
Application Number:	15154631
Application Number:	15205918
Application Number:	15205925
Application Number:	15241439
Application Number:	15310917
Application Number:	15311488
Application Number:	15346411
Application Number:	15376086
Application Number:	15527811
Application Number:	15638548
Application Number:	15708634
Application Number:	15921365
Application Number:	15955973
Application Number:	15994574
Application Number:	16007075
Application Number:	16250476
Application Number:	16263648
Application Number:	16303530
Application Number:	16358091
Application Number:	16417958
Application Number:	16432246
Application Number:	16515303
Application Number:	16615214
Application Number:	16615232

Property Type	Number
Application Number:	16685751
Application Number:	16746205
Application Number:	16778506
Application Number:	16855522
Application Number:	16860428
Application Number:	16930134
Application Number:	16975292
Application Number:	16981149
Application Number:	17031744
Application Number:	17052070
Application Number:	17170641
Application Number:	17175317
Application Number:	17186658
Application Number:	17197867
Application Number:	17199484
Application Number:	17295360
Application Number:	17295370
Application Number:	17344322
Application Number:	17470723
Application Number:	17480166
Application Number:	17504654
Application Number:	17576470
Application Number:	17668123
Application Number:	17845688
Application Number:	17883491
Application Number:	17893991
Application Number:	17930931
Application Number:	17942106
Application Number:	17942111
Application Number:	17942112
Application Number:	17942120
Application Number:	17942121
Application Number:	17942122
Application Number:	17942123
Application Number:	17946024
Application Number:	17946112
Application Number:	63234961
Application Number:	63239881

Property Type	Number
Application Number:	63241754
Application Number:	63273540
Application Number:	63307373
Application Number:	63310751
Application Number:	63369750
Application Number:	63378808
PCT Number:	CN2021117698
PCT Number:	US2021024077
PCT Number:	US2021042199
PCT Number:	US2021048199
PCT Number:	US2021057078
PCT Number:	US2021064810
PCT Number:	US2022020890
PCT Number:	US2022026769
PCT Number:	US2022027026
PCT Number:	US2022032629
PCT Number:	US2022040864
PCT Number:	US2022074622

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: GAhmadi@mofo.com

Correspondent Name: MORRISON & FOERSTER LLP

Address Line 1: 425 MARKET ST

Address Line 4: SAN FRANCISCO, CALIFORNIA 94105

ATTORNEY DOCKET NUMBER:	72388/26
NAME OF SUBMITTER:	GOLZAR SILLANPAA
SIGNATURE:	/Golzar Sillanpaa/
DATE SIGNED:	10/19/2022

Total Attachments: 27

source=Project Icon - 2L Patent Security Agreement#page1.tif
source=Project Icon - 2L Patent Security Agreement#page2.tif
source=Project Icon - 2L Patent Security Agreement#page3.tif
source=Project Icon - 2L Patent Security Agreement#page4.tif
source=Project Icon - 2L Patent Security Agreement#page5.tif
source=Project Icon - 2L Patent Security Agreement#page6.tif
source=Project Icon - 2L Patent Security Agreement#page7.tif
source=Project Icon - 2L Patent Security Agreement#page8.tif

source=Project Icon - 2L Patent Security Agreement#page9.tif
source=Project Icon - 2L Patent Security Agreement#page10.tif
source=Project Icon - 2L Patent Security Agreement#page11.tif
source=Project Icon - 2L Patent Security Agreement#page12.tif
source=Project Icon - 2L Patent Security Agreement#page13.tif
source=Project Icon - 2L Patent Security Agreement#page14.tif
source=Project Icon - 2L Patent Security Agreement#page15.tif
source=Project Icon - 2L Patent Security Agreement#page16.tif
source=Project Icon - 2L Patent Security Agreement#page17.tif
source=Project Icon - 2L Patent Security Agreement#page18.tif
source=Project Icon - 2L Patent Security Agreement#page19.tif
source=Project Icon - 2L Patent Security Agreement#page20.tif
source=Project Icon - 2L Patent Security Agreement#page21.tif
source=Project Icon - 2L Patent Security Agreement#page22.tif
source=Project Icon - 2L Patent Security Agreement#page23.tif
source=Project Icon - 2L Patent Security Agreement#page24.tif
source=Project Icon - 2L Patent Security Agreement#page25.tif
source=Project Icon - 2L Patent Security Agreement#page26.tif
source=Project Icon - 2L Patent Security Agreement#page27.tif

SECOND LIEN PATENT SECURITY AGREEMENT

THIS SECOND LIEN PATENT SECURITY AGREEMENT, dated as of October 19, 2022, is made by INSMED INCORPORATED (“Grantor”), in favor of ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP (together with its successors and permitted assigns, the “Purchaser”).

W I T N E S S E T H:

WHEREAS, pursuant to the Revenue Interest Purchase Agreement, dated as of October 19, 2022 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”), by and among INSMED INCORPORATED., a Virginia corporation (“Company”), and the Purchaser, the Purchaser has purchased the right to receive the Revenue Interest Payments from Company and Company has agreed to make the Revenue Interest Payments and the other payments required therein to Purchaser upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to the Second Lien Guaranty and Security Agreement dated as of October 19, 2022 in favor of the Purchaser (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the “Guaranty and Security Agreement”), to guarantee the Obligations (as defined in the Purchase Agreement) of the Company; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Patent Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Patent Collateral. Grantor (as sole and full owner of all Collateral subject to this Agreement), as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Purchaser, and grants to the Purchaser, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the “Patent Collateral”):

(a) all of its Patents that have been or will be issued or filed in any patent office or its equivalent anywhere in the world, including all future Patents, and all IP Licenses and IP Ancillary Rights providing for the grant by or to Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1 hereto;

(b) all reissues, reexaminations, subject of inter partes review, continuations, continuations-in-part, divisionals, substitutes, renewals patent extensions including any patent term extension, patent term adjustment, pediatric exclusivity, any supplementary protection certificate of the foregoing, and any patent issued with respect to any of the foregoing, and any confirmation patent or registration patent or patent of addition based on any such patent including, without limitation, those referred to on Schedule 1 hereto; and

(c) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Purchaser, pursuant to

the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of the Purchaser with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their Patents and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Patent Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

Section 6. Governing Law. THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN PATENT COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.

THE TERMS OF ARTICLE VII OF THE PURCHASE AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, *MUTATIS MUTANDIS*, AS IF SET FORTH IN FULL HEREIN AND THE PARTIES HERETO AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.

Section 7. Termination. Upon the absolute, unconditional and irrevocable payment in full of the Secured Obligations in accordance with the provisions of the Purchase Agreement, the security interest in the Patent Collateral granted hereby shall automatically terminate, without delivery of any instrument or performance of any act by any party, and all rights to the Patent Collateral shall automatically revert to Grantors or any other Person entitled thereto. At such time, the Purchaser authorizes the filing by such Grantor of an appropriate termination hereof.

Section 8. Intercreditor Agreement. Notwithstanding anything herein to the contrary, the security interest granted pursuant to this Patent Security Agreement, the terms of this Patent Security Agreement and the exercise of any right or remedy hereunder are subject to the provisions of the Intercreditor Agreement, dated as of October 19, 2022, by and between the Purchaser and BioPharma Credit PLC and acknowledged and agreed to by the Company (as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time).

IN WITNESS WHEREOF, Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

INSMED INCORPORATED

as Grantor DocuSigned by:


By: 
Name: Sara Bonstein
Title: Chief Financial Officer

ACCEPTED AND AGREED
as of the date first above written:

ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP

By: OrbiMed ROF IV LLC, its General Partner

By: OrbiMed Advisors LLC, its Managing Member

DocuSigned by:

By: _____
Name: Matthew Rizzo
Title: Member

Signature Page to 2L Patent Security Agreement

PATENT
REEL: 061727 FRAME: 0047

SCHEDULE I
TO
PATENT SECURITY AGREEMENT

Patent Registrations

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
INMD-004: METHODS OF TREATING PULMONARY DISORDERS WITH LIPOSOMAL AMIKACIN FORMULATIONS				
Assignee: Insmmed Incorporated				
United States of America	12/250,412	10/13/2008	9,114,081	8/25/2015
Australia	2009303542	10/13/2009	2009303542	8/28/2014
Germany	09821103.0	10/13/2009	2349282	1/15/2020
European Patent Office	09821103.0	10/13/2009	2349282	1/15/2020
Spain	09821103.0	10/13/2009	2349282	1/15/2020
France	09821103.0	10/13/2009	2349282	1/15/2020
United Kingdom	09821103.0	10/13/2009	2349282	1/15/2020
Italy	09821103.0	10/13/2009	2349282	1/15/2020
Japan	2011-532180	10/13/2009	5677695	1/9/2015
Republic of Korea	10-2011-7008430	10/13/2009	10-1735123	5/4/2017
Mexico	MX/a/2011/003760	10/13/2009	344476	12/16/2016
Netherlands	09821103.0	10/13/2009	2349282	1/15/2020
New Zealand	592217	10/13/2009	592217	7/2/2013
Russian Federation	2011119018	10/13/2009	2537238	10/31/2014
Australia	2014201765	10/13/2009	2014201765	3/23/2016
Japan	2014-75240	10/13/2009	6087862	2/10/2017
New Zealand	606383	10/13/2009	606383	1/6/2015
United States of America	13/480,246	5/24/2012	9,119,783	9/1/2015
United States of America	13/566,707	8/3/2012	9,333,214	5/10/2016
United States of America	14/809,127	7/24/2015	9,724,301	8/8/2017
United States of America	14/809,128	7/24/2015	9,737,555	8/22/2017
United States of America	15/638,548	6/30/2017	10,064,882	9/4/2018
INMD-012/01: SUSTAINED RELEASE OF ANTIINFECTIVES				
Assignee: Insmmed Incorporated or Insmmed, Inc.				
Austria	03816990.0	10/29/2003	1581236	10/16/2013
Australia	2003304204	10/29/2003	2003304204	4/8/2010
Belgium	03816990.0	10/29/2003	1581236	10/16/2013
Bulgaria	03816990.0	10/29/2003	1581236	10/16/2013
Canada	2504317	10/29/2003	2504317	5/22/2012
Switzerland	03816990.0	10/29/2003	1581236	10/16/2013
China	200380106534.2	10/29/2003	ZL 200380106534.2	11/24/2010
Cyprus	03816990.0	10/29/2003	1581236	10/16/2013
Czech Republic	03816990.0	10/29/2003	1581236	10/16/2013
Germany	03816990.0	10/29/2003	1581236	10/16/2013
Denmark	03816990.0	10/29/2003	1581236	10/16/2013

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Estonia	03816990.0	10/29/2003	1581236	10/16/2013
European Patent Office	03816990.0	10/29/2003	1581236	10/16/2013
Spain	03816990.0	10/29/2003	1581236	10/16/2013
Finland	03816990.0	10/29/2003	1581236	10/16/2013
France	03816990.0	10/29/2003	1581236	10/16/2013
United Kingdom	03816990.0	10/29/2003	1581236	10/16/2013
Greece	03816990.0	10/29/2003	1581236	10/16/2013
Hungary	03816990.0	10/29/2003	1581236	10/16/2013
Ireland	03816990.0	10/29/2003	1581236	10/16/2013
Israel	168279	10/29/2003	168279	10/1/2015
India	2219/DELNP/2005	10/29/2003	243438	10/18/2010
Italy	03816990.0	10/29/2003	1581236	10/16/2013
Japan	2005-500829	10/29/2003	5,118,302	10/26/2012
Republic of Korea	10-2005-7007679	10/29/2003	10-1301653	8/23/2013
Luxembourg	03816990.0	10/29/2003	1581236	10/16/2013
Monaco	03816990.0	10/29/2003	1581236	10/16/2013
Mexico	PA/a/2005/004580	10/29/2003	276999	7/1/2010
Netherlands	03816990.0	10/29/2003	1581236	10/16/2013
New Zealand	540087	10/29/2003	540087	1/8/2009
Portugal	03816990.0	10/29/2003	1581236	10/16/2013
Romania	03816990.0	10/29/2003	1581236	10/16/2013
Sweden	03816990.0	10/29/2003	1581236	10/16/2013
Slovenia	03816990.0	10/29/2003	1581236	10/16/2013
Slovakia	03816990.0	10/29/2003	1581236	10/16/2013
Turkey	03816990.0	10/29/2003	1581236	10/16/2013
United States of America	10/696,389	10/29/2003	7,544,369	6/9/2009
South Africa	2005/04281	10/29/2003	2005/04281	9/27/2006
INMD-012/02: SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed Incorporated				
Japan	2011-1318	10/29/2003	5411878	11/15/2013
Republic of Korea	10-2013-7010499	10/29/2003	10-1424980	7/24/2014
Mexico	MX/a/2010/000195	10/29/2003	318205	2/26/2014
INMD-012/03: SUSTAINED RELEASE OF ANTIINFECTIVES AMINOGLYCOSIDES Assignee: Insmmed Incorporated or Insmmed, Inc.				
Austria	06787716.7	7/19/2006	1909759	9/4/2013
Australia	2006270008	7/19/2006	2006270008	1/3/2013
Belgium	06787716.7	7/19/2006	1909759	9/4/2013
Bulgaria	06787716.7	7/19/2006	1909759	9/4/2013
Canada	2614764	7/19/2006	2614764	3/18/2014
Switzerland	06787716.7	7/19/2006	1909759	9/4/2013
China	200680034397.X	7/19/2006	ZL200680034397.X	8/7/2013
Costa Rica	9736	7/19/2006	2979	12/12/2013

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Cyprus	06787716.7	7/19/2006	1909759	9/4/2013
Czech Republic	06787716.7	7/19/2006	1909759	9/4/2013
Germany	06787716.7	7/19/2006	1909759	9/4/2013
Denmark	06787716.7	7/19/2006	1909759	9/4/2013
Estonia	06787716.7	7/19/2006	1909759	9/4/2013
European Patent Office	06787716.7	7/19/2006	1909759	9/4/2013
Spain	06787716.7	7/19/2006	1909759	9/4/2013
Finland	06787716.7	7/19/2006	1909759	9/4/2013
France	06787716.7	7/19/2006	1909759	9/4/2013
United Kingdom	06787716.7	7/19/2006	1909759	9/4/2013
Greece	06787716.7	7/19/2006	1909759	9/4/2013
Hong Kong	09102316.4	7/19/2006	1124770	1/30/2014
Honduras	2008-84	7/19/2006	4987	1/24/2011
Hungary	06787716.7	7/19/2006	1909759	9/4/2013
Ireland	06787716.7	7/19/2006	1909759	9/4/2013
India	353/DELNP/2008	7/19/2006	276035	9/29/2016
Iceland	06787716.7	7/19/2006	1909759	9/4/2013
Italy	06787716.7	7/19/2006	1909759	9/4/2013
Japan	2008-522895	7/19/2006	5415759	11/22/2013
Republic of Korea	10-2008-7002031	7/19/2006	10-1358660	1/28/2014
Kosovo	KSA/2008/000861	7/19/2006	861	5/2/2012
Lithuania	06787716.7	7/19/2006	1909759	9/4/2013
Luxembourg	06787716.7	7/19/2006	1909759	9/4/2013
Latvia	06787716.7	7/19/2006	1909759	9/4/2013
Monaco	06787716.7	7/19/2006	1909759	9/4/2013
Montenegro	P-68/2009	7/19/2006	00597	8/16/2011
Mexico	MX/a/2008/000425	7/19/2006	280091	10/18/2010
Netherlands	06787716.7	7/19/2006	1909759	9/4/2013
New Zealand	565300	7/19/2006	565300	11/7/2011
Poland	06787716.7	7/19/2006	1909759	9/4/2013
Portugal	06787716.7	7/19/2006	1909759	9/4/2013
Romania	06787716.7	7/19/2006	1909759	9/4/2013
Russian Federation	2008102651	7/19/2006	2438655	1/10/2012
Sweden	06787716.7	7/19/2006	1909759	9/4/2013
Singapore	200800137-2	7/19/2006	138968	8/31/2010
Slovakia	06787716.7	7/19/2006	1909759	9/4/2013
Slovenia	06787716.7	7/19/2006	1909759	9/4/2013
Turkey	06787716.7	7/19/2006	1909759	9/4/2013
United States of America	11/185,448	7/19/2005	7,718,189	5/18/2010
South Africa	2008/00367	7/19/2006	2008/00367	12/31/2008

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
INMD-012/04: SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed Incorporated				
China	201310149581.0	7/19/2006	ZL201310149581.0	3/29/2019
Hong Kong	13112330.9	7/19/2006	HK1184711	5/15/2020
Israel	216401	7/19/2006	216401	2/1/2018
India	6406/DELNP/2014	7/19/2006		
Republic of Korea	10-2013-7031379	7/19/2006	10-1437338	8/28/2014
INMD-012/05: SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed Incorporated or Insmmed, Inc.				
Canada	2838108	7/19/2006	2838108	5/17/2016
Israel	236190	10/29/2003	236190	11/30/2019
Japan	2013-146934	7/19/2006	5800865	9/4/2015
Republic of Korea	10-2014-7005780	10/29/2003	10-1504616	3/16/2015
Mexico	2013-013982	10/29/2003	353044	12/18/2017
INMD-012/06: SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed, Inc.				
Hong Kong	14103632.2	7/19/2006		
Japan	2013-167610	10/29/2003	5684343	1/23/2015
United States of America	12/748,756	3/29/2010	8,802,137	8/12/2014
INMD-012/08: LIPOSOMES COMPRISING AN AMINOGLYCOSIDE FOR THE TREATMENT OF PULMONARY INFECTIONS / SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed Incorporated or Insmmed, Inc.				
Germany	14183066.1	10/29/2003	2823820	6/6/2018
European Patent Office	14183066.1	10/29/2003	2823820	6/6/2018
Spain	14183066.1	10/29/2003	2823820	6/6/2018
France	14183066.1	10/29/2003	2823820	6/6/2018
United Kingdom	14183066.1	10/29/2003	2823820	6/6/2018
Hong Kong	15102375.4	10/29/2003	HK1201749	7/5/2019
Italy	14183066.1	10/29/2003	2823820	6/6/2018
Japan	2014-196130	7/19/2006	5902782	3/18/2016
Netherlands	14183066.1	10/29/2003	2823820	6/6/2018
United States of America	14/319,018	6/30/2014	9,827,317	11/28/2017
INMD-012/10: LIPOSOMES COMPRISING AN AMINOGLYCOSIDE FOR THE TREATMENT OF PULMONARY INFECTIONS Assignee: Insmmed Incorporated				
Switzerland	18176134.7	10/29/2003	3427742	8/12/2020
Germany	603 52 555.5	10/29/2003	3427742	8/12/2020
European Patent Office	18176134.7	10/29/2003	3427742	8/12/2020
Spain	18176134.7	10/29/2003	3427742	8/12/2020
France	18176134.7	10/29/2003	3427742	8/12/2020
United Kingdom	18176134.7	10/29/2003	3427742	8/12/2020
Italy	18176134.7	10/29/2003	3427742	8/12/2020
Japan	2016-003289	7/19/2006	6125676	4/14/2017
Monaco	18176134.7	10/29/2003	3427742	8/12/2020
Netherlands	18176134.7	10/29/2003	3427742	8/12/2020

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Turkey	18176134.7	10/29/2003	3427742	8/12/2020
INMD-012/11: SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed Incorporated				
Japan	2016-29641	10/29/2003	6130946	4/21/2017
INMD-012/23 to 24: SUSTAINED RELEASE OF ANTIINFECTIVES Assignee: Insmmed Incorporated				
United States of America	17/197,867	3/10/2021		
United States of America	17/930,931	9/9/2022		
INMD-015/01: PURIFIED RHIGF-I/RHIGFBP-3 COMPLEXES AND THEIR METHOD OF MANUFACTURE Assignee: Insmmed, Inc.				
Austria	E459637	12/20/2005	E459637	3/3/2010
Belgium	05854704.3	12/20/2005	1828225	3/3/2010
Canada	2592014	12/20/2005	2592014	11/24/2015
Switzerland	05854704.3	12/20/2005	1828225	3/3/2010
Germany	602005019784-2	12/20/2005	602005019784-2	3/3/2010
European Patent Office	05854704.3	12/20/2005	1828225	3/3/2010
Spain	05854704.3	12/20/2005	1828225	3/3/2010
France	05854704.3	12/20/2005	1828225	3/3/2010
United Kingdom	05854704.3	12/20/2005	1828225	3/3/2010
Greece	05854704.3	12/20/2005	1828225	3/3/2010
Hungary	05854704.3	12/20/2005	1828225	3/3/2010
Ireland	05854704.3	12/20/2005	1828225	3/3/2010
Italy	05854704.3	12/20/2005	1828225	3/3/2010
Lithuania	5854704.3	12/20/2005	EP1828225	3/3/2010
Luxembourg	05854704.3	12/20/2005	1828225	3/3/2010
Netherlands	05854704.3	12/20/2005	1828225	3/3/2010
Poland	05854704.3	12/20/2005	1828225	3/3/2010
Romania	05854704.3	12/20/2005	1828225	3/3/2010
Sweden	5854704.3	12/20/2005	05854704-3	3/3/2010
United States of America	11/311,633	12/20/2005	7,968,679	6/28/2011
INMD-018/01: LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS Assignee: Insmmed Incorporated				
Austria	06847502.9	12/5/2006	1962805	7/6/2016
Australia	2006322076	12/5/2006	2006322076	10/31/2013
Belgium	06847502.9	12/5/2006	1962805	7/6/2016
Bulgaria	06847502.9	12/5/2006	1962805	7/6/2016
Canada	2631872	12/5/2006	2631872	4/1/2014
Switzerland	06847502.9	12/5/2006	1962805	7/6/2016
Cyprus	06847502.9	12/5/2006	1962805	7/6/2016
Czech Republic	06847502.9	12/5/2006	1962805	7/6/2016
Germany	06847502.9	12/5/2006	1962805	7/6/2016
Denmark	06847502.9	12/5/2006	1962805	7/6/2016
Estonia	06847502.9	12/5/2006	1962805	7/6/2016

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
European Patent Office	06847502.9	12/5/2006	1962805	7/6/2016
Spain	06847502.9	12/5/2006	1962805	7/6/2016
Finland	06847502.9	12/5/2006	1962805	7/6/2016
France	06847502.9	12/5/2006	1962805	7/6/2016
United Kingdom	06847502.9	12/5/2006	1962805	7/6/2016
Greece	06847502.9	12/5/2006	1962805	7/6/2016
Hungary	06847502.9	12/5/2006	1962805	7/6/2016
Ireland	06847502.9	12/5/2006	1962805	7/6/2016
Iceland	06847502.9	12/5/2006	1962805	7/6/2016
Italy	06847502.9	12/5/2006	1962805	7/6/2016
Japan	2008-544430	12/5/2006	5324223	7/26/2013
Lithuania	06847502.9	12/5/2006	1962805	7/6/2016
Luxembourg	06847502.9	12/5/2006	1962805	7/6/2016
Latvia	06847502.9	12/5/2006	1962805	7/6/2016
Monaco	06847502.9	12/5/2006	1962805	7/6/2016
Netherlands	06847502.9	12/5/2006	1962805	7/6/2016
Poland	06847502.9	12/5/2006	1962805	7/6/2016
Portugal	06847502.9	12/5/2006	1962805	7/6/2016
Romania	06847502.9	12/5/2006	1962805	7/6/2016
Sweden	06847502.9	12/5/2006	1962805	7/6/2016
Slovenia	06847502.9	12/5/2006	1962805	7/6/2016
Slovakia	06847502.9	12/5/2006	1962805	7/6/2016
Turkey	06847502.9	12/5/2006	1962805	7/6/2016
United States of America	11/634,343	12/5/2006	8,226,975	7/24/2012
INMD-018/02: LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF Assignee: Insmmed Incorporated				
Canada	2838111	12/5/2006	2838111	Canada
Germany	16156100.6	12/5/2006	3067047	Germany
European Patent Office	16156100.6	12/5/2006	3067047	European Patent Office
United Kingdom	16156100.6	12/5/2006	3067047	United Kingdom
Hong Kong	16113514.2	11/25/2016		Hong Kong
United States of America	13/527,213	6/19/2012	8,632,804	United States of America
INMD-018/03 to 17: LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF Assignee: Insmmed Incorporated or Insmmed, Inc.				
Belgium	16156099.0	12/5/2006	3067046	3/25/2020
Switzerland	16156099.0	12/5/2006	3067046	3/25/2020
Germany	16156099.0	12/5/2006	3067046	3/25/2020
European Patent Office	16156099.0	12/5/2006	3067046	3/25/2020
Spain	16156099.0	12/5/2006	3067046	3/25/2020
France	16156099.0	12/5/2006	3067046	3/25/2020

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
United Kingdom	16156099.0	12/5/2006	3067046	3/25/2020
Hong Kong	17102333.3	12/5/2006	HK1228744	3/12/2021
Ireland	16156099.0	12/5/2006	3067046	3/25/2020
Italy	16156099.0	12/5/2006	3067046	3/25/2020
Netherlands	16156099.0	12/5/2006	3067046	3/25/2020
Sweden	16156099.0	12/5/2006	3067046	3/25/2020
United States of America	13/664,181	10/30/2012	8,679,532	3/25/2014
United States of America	13/666,420	11/1/2012	8,642,075	2/4/2014
United States of America	13/675,559	11/13/2012	8,673,348	3/18/2014
United States of America	13/675,587	11/13/2012	8,673,349	3/18/2014
United States of America	14/987,508	1/4/2016	9,402,845	8/2/2016
United States of America	15/205,918	7/8/2016	9,511,082	12/6/2016
United States of America	15/205,925	7/8/2016	9,549,939	1/24/2017
United States of America	15/241,439	8/19/2016	9,549,925	1/24/2017
United States of America	15/376,086	12/12/2016	10,328,071	6/25/2019
United States of America	16/746,205	1/17/2020		
INMD-047/01 to 03: METHODS FOR COACERVATION INDUCED LIPOSOMAL ENCAPSULATION AND FORMULATIONS THEREOF				
Assignee: Insmmed Incorporated				
Germany	07754936.8	4/4/2007	2012750	2/21/2018
European Patent Office	07754936.8	4/4/2007	2012750	2/21/2018
Spain	07754936.8	4/4/2007	2012750	2/21/2018
France	07754936.8	4/4/2007	2012750	2/21/2018
United Kingdom	07754936.8	4/4/2007	2012750	2/21/2018
Italy	07754936.8	4/4/2007	2012750	2/21/2018
Japan	2009-504301	4/4/2007	5600432	8/22/2014
Netherlands	07754936.8	4/4/2007	2012750	2/21/2018
Germany	17207115.1	4/4/2007	602007053968.4	12/9/2020
European Patent Office	17207115.1	4/4/2007	3354260	12/9/2020
France	17207115.1	4/4/2007	3354260	12/9/2020
United Kingdom	17207115.1	4/4/2007	3354260	12/9/2020
Netherlands	17207115.1	4/4/2007	3354260	12/9/2020
Japan	2014-165736	4/4/2007	6088469	2/10/2017
INMD-048/01: RECOMBINANT IGF EXPRESSION SYSTEMS				
Assignee: Insmmed, Inc.				
Belgium	04755315.1	6/14/2004	1646650	4/22/2009
Canada	2529282	6/14/2004	2529282	5/28/2013
European Patent Office	04755315.1	6/14/2004	1646650	4/22/2009
United Kingdom	04755315.1	6/14/2004	1646650	4/22/2009
Hungary	04755315.1	6/14/2004	E006533	4/22/2009
Ireland	04755315.1	6/14/2004	1646650	4/22/2009
United States of America	10/866,086	6/14/2004	7,354,994	4/8/2008

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
INMD-050/02: METHOD FOR USE OF IGF-BINDING PROTEIN FOR SELECTIVE SENSITIZATION OF TARGET CELLS IN VIVO				
Assignee: Bioexpertise, LLC				
United States of America	10/778,636	2/13/2004	7,371,813	5/13/2008
INMD-056/01 to 08: SYSTEMS FOR TREATING PULMONARY INFECTIONS				
Assignee: Insmed Incorporated				
Australia	2013266400	5/21/2013	2013266400	10/5/2017
Brazil	1120140290105	5/21/2013	112014029010-5	11/17/2020
Canada	2870860	5/21/2013	2870860	7/27/2021
China	201380030763.4	5/21/2013	ZL201380030763.4	7/13/2018
European Patent Office	13793204.2	5/21/2013	2852391	11/17/2021
Austria	13793204.2	5/21/2013	2852391	11/17/2021
Switzerland	13793204.2	5/21/2013	2852391	11/17/2021
Cyprus	13793204.2	5/21/2013	2852391	11/17/2021
Czech Republic	13793204.2	5/21/2013	2852391	11/17/2021
Germany	13793204.2	5/21/2013	2852391	11/17/2021
Denmark	13793204.2	5/21/2013	2852391	11/17/2021
Estonia	13793204.2	5/21/2013	2852391	11/17/2021
Spain	13793204.2	5/21/2013	2852391	11/17/2021
Finland	13793204.2	5/21/2013	2852391	11/17/2021
France	13793204.2	5/21/2013	2852391	11/17/2021
United Kingdom	13793204.2	5/21/2013	2852391	11/17/2021
Greece	13793204.2	5/21/2013	2852391	11/17/2021
Croatia	13793204.2	5/21/2013	2852391	11/17/2021
Ireland	13793204.2	5/21/2013	2852391	11/17/2021
Italy	13793204.2	5/21/2013	2852391	11/17/2021
Lithuania	13793204.2	5/21/2013	2852391	11/17/2021
Luxembourg	13793204.2	5/21/2013	2852391	11/17/2021
Latvia	13793204.2	5/21/2013	2852391	11/17/2021
Malta	13793204.2	5/21/2013	2852391	11/17/2021
Netherlands	13793204.2	5/21/2013	2852391	11/17/2021
Norway	13793204.2	5/21/2013	2852391	11/17/2021
Poland	13793204.2	5/21/2013	2852391	11/17/2021
Portugal	13793204.2	5/21/2013	2852391	11/17/2021
Sweden	13793204.2	5/21/2013	2852391	11/17/2021
Slovenia	13793204.2	5/21/2013	2852391	11/17/2021
Slovakia	13793204.2	5/21/2013	2852391	11/17/2021
Turkey	13793204.2	5/21/2013	2852391	11/17/2021
Belgium	13793204.2	5/21/2013	2852391	11/17/2021
Monaco	13793204.2	5/21/2013	2852391	11/17/2021
Hong Kong	15103492.0	5/21/2013	HK1202812	7/8/2022
Israel	234898	5/21/2013	234898	10/31/2020

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
India	9003/DELNP/2014	5/21/2013	326704	12/3/2019
Japan	2015-514136	5/21/2013	6402097	9/14/2018
Republic of Korea	10-2014-7035838	5/21/2013	10-2092361	3/17/2020
Mexico	MX/a/2014/014219	5/21/2013	369828	11/22/2019
New Zealand	700983	5/21/2013	700983	1/31/2017
Russian Federation	2014151554	5/21/2013	2657510	6/14/2018
United States of America	13/899,457	5/21/2013	9,566,234	2/14/2017
Australia	2017225138	5/21/2013	2017225138	7/4/2019
China	201810699987.9	5/21/2013	ZL201810699987.9	6/11/2021
European Patent Office	21207734.1	5/21/2013		
Hong Kong	19122586.1	5/21/2013		
Republic of Korea	10-2020-7007836	5/21/2013	10-2277921	7/9/2021
Macau	J/005258	5/21/2013		
New Zealand	719739	5/21/2013	719739	10/31/2017
Australia	2019204100	5/21/2013	2019204100	7/23/2020
Japan	2019-226642	5/21/2013	6980745	11/19/2021
Japan	2021-134797	5/21/2013		
United States of America	17/175,317	2/12/2021		
INMD-096/01: STABILIZED VANCOMYCIN FORMULATIONS				
Assignee: Insmid Incorporated				
European Patent Office	13858844.7	11/27/2013	2925298B	5/29/2019
France	13858844.7	11/27/2013	2925298B	5/29/2019
Great Britain	13858844.7	11/27/2013	2925298B	5/29/2019
Germany	13858844.7	11/27/2013	2925298B	5/29/2019
Japan	2015-545418	11/27/2013	6529438	5/24/2019
Russian Federation	2015125293	11/27/2013	2675859	12/25/2018
INMD-117/01: PROSTACYLIN COMPOSITIONS AND METHODS FOR USING THE SAME				
Assignee: Insmid Incorporated				
Japan	2015-545499	12/2/2013	6357481	6/22/2018
INMD-120/05 to 12: PROSTACYLIN COMPOUNDS (, COMPOSITIONS AND METHODS OF USE THEREOF)				
Assignee: Insmid Incorporated				
Austria	14855785.3	10/24/2014	3060041	12/16/2020
Australia	2014339866	10/24/2014	2014339866	9/13/2018
Belgium	14855785.3	10/24/2014	3060041	12/16/2020
Brazil	1120160092074	10/24/2014		
Canada	2927788	10/24/2014	2927788	9/6/2022
Switzerland	14855785.3	10/24/2014	3060041	12/16/2020
China	201480070936.X	10/24/2014	ZL201480070936.X	7/13/2018
Cyprus	14855785.3	10/24/2014	3060041	12/16/2020
Czech Republic	14855785.3	10/24/2014	3060041	12/16/2020
Germany	14855785.3	10/24/2014	3060041	12/16/2020
Denmark	14855785.3	10/24/2014	3060041	12/16/2020

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Eurasian Patent Organization	201690623	10/24/2014	031604	1/31/2019
Estonia	14855785.3	10/24/2014	3060041	12/16/2020
European Patent Office	14855785.3	10/24/2014	3060041	12/16/2020
Spain	14855785.3	10/24/2014	3060041	12/16/2020
Finland	14855785.3	10/24/2014	3060041	12/16/2020
France	14855785.3	10/24/2014	3060041	12/16/2020
United Kingdom	14855785.3	10/24/2014	3060041	12/16/2020
Greece	14855785.3	10/24/2014	3060041	12/16/2020
Hong Kong	16113543.7	10/24/2014	1225229	7/23/2021
Croatia	14855785.3	10/24/2014	3060041	12/16/2020
Ireland	14855785.3	10/24/2014	3060041	12/16/2020
Israel	245184	10/24/2014	245184	5/28/2020
Italy	14855785.3	10/24/2014	3060041	12/16/2020
Japan	2016-525531	10/24/2014	6491203	3/8/2019
Republic of Korea	10-2016-7013749	10/24/2014	10-2296259	8/25/2021
Lithuania	14855785.3	10/24/2014	3060041	12/16/2020
Luxembourg	14855785.3	10/24/2014	3060041	12/16/2020
Latvia	14855785.3	10/24/2014	3060041	12/16/2020
Monaco	14855785.3	10/24/2014	3060041	12/16/2020
Malta	14855785.3	10/24/2014	3060041	12/16/2020
Mexico	MX/a/2016/005293	10/24/2014	378013	12/7/2020
Netherlands	14855785.3	10/24/2014	3060041	12/16/2020
Norway	14855785.3	10/24/2014	3060041	12/16/2020
New Zealand	719297	10/24/2014	719297	6/29/2021
Poland	14855785.3	10/24/2014	3060041	12/16/2020
Portugal	14855785.3	10/24/2014	3060041	12/16/2020
Sweden	14855785.3	10/24/2014	3060041	12/16/2020
Slovenia	14855785.3	10/24/2014	3060041	12/16/2020
Slovakia	14855785.3	10/24/2014	3060041	12/16/2020
Turkey	14855785.3	10/24/2014	3060041	12/16/2020
United States of America	14/523,538	10/24/2014	9,469,600	10/18/2016
Australia	2018204198	10/24/2014	2018204198	11/7/2019
European Patent Office	20213903.6	10/24/2014		
Hong Kong	19124833.5	10/24/2014		
Japan	2018-248772	10/24/2014	6722268	6/23/2020
Republic of Korea	10-2021-7027153	10/24/2014		
Mexico	MX/a/2020/004912	10/24/2014	382833	5/21/2021
New Zealand	758464	10/24/2014	758464	6/29/2021
Australia	2019240559	10/24/2014	2019240559	7/23/2020
Hong Kong	42021040680.7	10/24/2014		

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Japan	2020-85701	10/24/2014	6967111	10/26/2021
United States of America	14/641,104	3/6/2015	9,255,064	2/9/2016
Japan	2021-146084	10/24/2014		
United States of America	15/154,631	5/13/2016	10,010,518	7/3/2018
United States of America	15/994,574	5/31/2018	10,526,274	1/7/2020
United States of America	16/685,751	11/15/2019	10,995,055	5/4/2021
United States of America	17/186,658	2/26/2021		
INMD-122/04 to 15: METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS				
Assignee: Insmid Incorporated or Insmid, Inc.				
United States of America	14/713,926	5/15/2015	9,895,385	2/20/2018
Albania	15791964.8	5/15/2015	3142643	7/10/2019
Austria	15791964.8	5/15/2015	3142643	7/10/2019
Australia	2015258947	5/15/2015	2015258947	7/23/2020
Bosnia & Herzegovina	15791964.8	5/15/2015	3142643	7/10/2019
Belgium	15791964.8	5/15/2015	3142643	7/10/2019
Bulgaria	15791964.8	5/15/2015	3142643	7/10/2019
Brazil	1120160266994	5/15/2015		
Canada	2949078	5/15/2015		
Switzerland	15791964.8	5/15/2015	3142643	7/10/2019
Cyprus	15791964.8	5/15/2015	3142643	7/10/2019
Czech Republic	15791964.8	5/15/2015	3142643	7/10/2019
Germany	15791964.8	5/15/2015	3142643	7/10/2019
Denmark	15791964.8	5/15/2015	3142643	7/10/2019
Estonia	15791964.8	5/15/2015	3142643	7/10/2019
European Patent Office	15791964.8	5/15/2015	3142643	7/10/2019
Spain	15791964.8	5/15/2015	3142643	7/10/2019
Finland	15791964.8	5/15/2015	3142643	7/10/2019
France	15791964.8	5/15/2015	3142643	7/10/2019
United Kingdom	15791964.8	5/15/2015	3142643	7/10/2019
Greece	15791964.8	5/15/2015	3142643	7/10/2019
Hong Kong	17104884.2	5/15/2015	1230985	7/3/2020
Croatia	15791964.8	5/15/2015	3142643	7/10/2019
Hungary	15791964.8	5/15/2015	3142643	7/10/2019
Ireland	15791964.8	5/15/2015	3142643	7/10/2019
Iceland	15791964.8	5/15/2015	3142643	7/10/2019
Italy	15791964.8	5/15/2015	3142643	7/10/2019
Japan	2017-512871	5/15/2015	6646653	1/15/2020
Republic of Korea	10-2016-7035068	5/15/2015		
Lithuania	15791964.8	5/15/2015	3142643	7/10/2019
Luxembourg	15791964.8	5/15/2015	3142643	7/10/2019
Latvia	15791964.8	5/15/2015	3142643	7/10/2019

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Monaco	15791964.8	5/15/2015	3142643	7/10/2019
Montenegro	15791964.8	5/15/2015	3142643	7/10/2019
Macedonia (F.Y.R.O.M)	15791964.8	5/15/2015	3142643	7/10/2019
Malta	15791964.8	5/15/2015	3142643	7/10/2019
Mexico	MX/a/2016/014921	5/15/2015	376012	10/12/2020
Netherlands	15791964.8	5/15/2015	3142643	7/10/2019
Norway	15791964.8	5/15/2015	3142643	7/10/2019
New Zealand	726256	5/15/2015		
Poland	15791964.8	5/15/2015	3142643	7/10/2019
Portugal	15791964.8	5/15/2015	3142643	7/10/2019
Romania	15791964.8	5/15/2015	3142643	7/10/2019
Serbia	15791964.8	5/15/2015	3142643	7/10/2019
Sweden	15791964.8	5/15/2015	3142643	7/10/2019
Slovenia	15791964.8	5/15/2015	3142643	7/10/2019
Slovakia	15791964.8	5/15/2015	3142643	7/10/2019
San Marino	15791964.8	5/15/2015	3142643	7/10/2019
Turkey	15791964.8	5/15/2015	3142643	7/10/2019
United States of America	15/311,488	5/15/2015	10,238,675	3/26/2019
Albania	18203799.4	5/15/2015	3466432	7/8/2020
Austria	18203799.4	5/15/2015	3466432	7/8/2020
Australia	2020204530	5/15/2015		
Belgium	18203799.4	5/15/2015	3466432	7/8/2020
Bulgaria	18203799.4	5/15/2015	3466432	7/8/2020
Brazil	BR1220200207230	5/15/2015		
Switzerland	18203799.4	5/15/2015	3466432	7/8/2020
Cyprus	18203799.4	5/15/2015	3466432	7/8/2020
Czech Republic	18203799.4	5/15/2015	3466432	7/8/2020
Germany	18203799.4	5/15/2015	3466432	7/8/2020
Denmark	18203799.4	5/15/2015	3466432	7/8/2020
Estonia	18203799.4	5/15/2015	3466432	7/8/2020
European Patent Office	18203799.4	5/15/2015	3466432	7/8/2020
Spain	18203799.4	5/15/2015	3466432	7/8/2020
Finland	18203799.4	5/15/2015	3466432	7/8/2020
France	18203799.4	5/15/2015	3466432	7/8/2020
United Kingdom	18203799.4	5/15/2015	3466432	7/8/2020
Greece	18203799.4	5/15/2015	3466432	7/8/2020
Hong Kong	19130438.5	5/15/2015	40006986	3/12/2021
Croatia	18203799.4	5/15/2015	3466432	7/8/2020
Hungary	18203799.4	5/15/2015	3466432	7/8/2020
Ireland	18203799.4	5/15/2015	3466432	7/8/2020

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Iceland	18203799.4	5/15/2015	3466432	7/8/2020
Italy	18203799.4	5/15/2015	3466432	7/8/2020
Japan	2020-002791	5/15/2015	6892529	5/31/2021
Republic of Korea	10-2022-7032656	5/15/2015		
Lithuania	18203799.4	5/15/2015	3466432	7/8/2020
Luxembourg	18203799.4	5/15/2015	3466432	7/8/2020
Latvia	18203799.4	5/15/2015	3466432	7/8/2020
Monaco	18203799.4	5/15/2015	3466432	7/8/2020
Macedonia (F.Y.R.O.M)	18203799.4	5/15/2015	3466432	7/8/2020
Malta	18203799.4	5/15/2015	3466432	7/8/2020
Mexico	MX/a/2020/010726	5/15/2015	NOT ASSIGNED YET	7/27/2021
Netherlands	18203799.4	5/15/2015	3466432	7/8/2020
Norway	18203799.4	5/15/2015	3466432	7/8/2020
Poland	18203799.4	5/15/2015	3466432	7/8/2020
Portugal	18203799.4	5/15/2015	3466432	7/8/2020
Romania	18203799.4	5/15/2015	3466432	7/8/2020
Serbia	18203799.4	5/15/2015	3466432	7/8/2020
Sweden	18203799.4	5/15/2015	3466432	7/8/2020
Slovenia	18203799.4	5/15/2015	3466432	7/8/2020
Slovakia	18203799.4	5/15/2015	3466432	7/8/2020
San Marino	18203799.4	5/15/2015	3466432	7/8/2020
Turkey	18203799.4	5/15/2015	3466432	7/8/2020
Switzerland	20182665.8	5/15/2015	3766501	7/6/2022
Germany	20182665.8	5/15/2015	3766501	7/6/2022
European Patent Office	20182665.8	5/15/2015	3766501	7/6/2022
Spain	20182665.8	5/15/2015	3766501	7/6/2022
France	20182665.8	5/15/2015	3766501	7/6/2022
United Kingdom	20182665.8	5/15/2015	3766501	7/6/2022
Hong Kong	42021033511.3	5/15/2015		
Ireland	20182665.8	5/15/2015	3766501	7/6/2022
Italy	20182665.8	5/15/2015	3766501	7/6/2022
Japan	2021-089011	5/15/2015		
Netherlands	20182665.8	5/15/2015	3766501	7/6/2022
United States of America	16/007,075	6/13/2018	10,251,900	4/9/2019
European Patent Office	22182229.9	5/15/2015		
United States of America	16/250,476	1/17/2019	10,398,719	9/3/2019
United States of America	16/263,648	1/31/2019	10,751,355	8/25/2020
United States of America	16/515,303	7/18/2019	10,588,918	3/17/2020
United States of America	16/778,506	1/31/2020	10,828,314	11/10/2020
United States of America	16/930,134	7/15/2020	11,446,318	9/20/2022

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
United States of America	17/031,744	9/24/2020	11,395,830	7/26/2022
United States of America	17/845,688	6/21/2022		
United States of America	17/883,491	8/8/2022		
INMD-125/01: COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASE AND LUNG INJURY Assignee: Insmmed Incorporated or Insmmed, Inc.				
Australia	2016291228	7/11/2016	2016291228	7/23/2020
Canada	2989884	7/11/2016		
Germany	16822088.7	7/11/2016	3319976	9/1/2021
European Patent Office	16822088.7	7/11/2016	3319976	9/1/2021
Spain	16822088.7	7/11/2016	3319976	9/1/2021
France	16822088.7	7/11/2016	3319976	9/1/2021
United Kingdom	16822088.7	7/11/2016	3319976	9/1/2021
Japan	2017-566354	7/11/2016	6884714	5/14/2021
Netherlands	16822088.7	7/11/2016	3319976	9/1/2021
INMD-127/01 to 03: METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS Assignee: Insmmed Incorporated or Insmmed, Inc.				
Australia	2015349969	11/18/2015	2015349969	5/21/2020
Canada	2967385	11/18/2015		
Germany	15862092.2	11/18/2015	3221291	3/31/2021
European Patent Office	15862092.2	11/18/2015	3221291	3/31/2021
Spain	15862092.2	11/18/2015	3221291	3/31/2021
France	15862092.2	11/18/2015	3221291	3/31/2021
United Kingdom	15862092.2	11/18/2015	3221291	3/31/2021
Hong Kong	18104145.6	11/18/2015	1244783	8/20/2021
Italy	15862092.2	11/18/2015	3221291	3/31/2021
Japan	2017-526523	11/18/2015	6866043	4/9/2021
Netherlands	15862092.2	11/18/2015	3221291	3/31/2021
United States of America	15/527,811	11/18/2015	10,343,979	7/9/2019
United States of America	16/417,958	5/21/2019	11,148,997	10/19/2021
United States of America	17/470,723	9/9/2021		
INMD-131/01 to 03: CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS Assignee: Insmmed, Inc. and AstraZeneca AB				
European Patent Office	17835331.4	7/28/2017		
Hong Kong	19132654.5	7/28/2017		
Japan	2019-504932	7/28/2017		
Republic of Korea	10-2019-7005469	7/28/2017		
Japan	2022-075836	7/28/2017		
United States of America	17/576,470	1/14/2022		
INMD-132/01 to 15: CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Assignee: AstraZeneca AB				
Anguilla	AI/A/2020/00254	1/23/2015	AI/A/2020/00254	1/4/2021
Albania	15701577.7	1/23/2015	3097086	12/13/2017

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
African Regional Intellectual Property Organization	AP/P/2016/009322	1/23/2015		
Argentina	20150100202	1/23/2015		
Austria	15701577.7	1/23/2015	3097086	12/13/2017
Australia	2015208932	1/23/2015	2015208932	6/1/2017
Belgium	15701577.7	1/23/2015	3097086	12/13/2017
Bulgaria	15701577.7	1/23/2015	3097086	12/13/2017
Bermuda	680EP	1/23/2015	680EP	10/28/2021
Brazil	BR112016016224-2	1/23/2015		
Canada	2935625	1/23/2015		
Switzerland	15701577.7	1/23/2015	3097086	12/13/2017
Chile	201601889	1/23/2015	57.705	7/3/2019
China	201580005484.1	1/23/2015	ZL201580005484.1	8/23/2019
Colombia	NC2016/0000289	1/23/2015	35946	9/4/2019
Cyprus, Northern (Turkish)	272	1/23/2015	272	12/4/2020
Cyprus	15701577.7	1/23/2015	3097086	12/13/2017
Czech Republic	15701577.7	1/23/2015	3097086	12/13/2017
Germany	15701577.7	1/23/2015	3097086	12/13/2017
Denmark	15701577.7	1/23/2015	3097086	12/13/2017
Eurasian Patent Organization	201691375	1/23/2015	032794	7/31/2019
Estonia	15701577.7	1/23/2015	3097086	12/13/2017
Egypt	1200/2016	1/23/2015		
European Patent Office	15701577.7	1/23/2015	3097086	12/13/2017
Spain	15701577.7	1/23/2015	3097086	12/13/2017
Finland	15701577.7	1/23/2015	3097086	12/13/2017
Fiji	1346	1/23/2015	1346	11/9/2020
Falkland Islands	16410	1/23/2015	3097086	11/4/2020
France	15701577.7	1/23/2015	3097086	12/13/2017
United Kingdom	15701577.7	1/23/2015	3097086	12/13/2017
Gulf Co-Operation Council	GC 2015-28809	1/22/2015	GC0009382	12/17/2018
Grenada		11/26/2020	12 of 2020	11/26/2020
Gibraltar	896	1/23/2015	896	11/12/2020
Greece	15701577.7	1/23/2015	3097086	12/13/2017
Guernsey		1/23/2015	GG-GP611	11/5/2020
Guyana	1756	1/23/2015	3097086	
Hong Kong	16114117.1	1/23/2015	1225730	11/16/2018
Croatia	15701577.7	1/23/2015	3097086	12/13/2017
Hungary	15701577.7	1/23/2015	3097086	12/13/2017
Indonesia	P00201605539	1/23/2015	IDP000063261	10/7/2019
Ireland	15701577.7	1/23/2015	3097086	12/13/2017
Israel	246614	1/23/2015	246614	5/29/2018

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
India	201627024223	1/23/2015	353200	12/8/2020
Iceland	15701577.7	1/23/2015	3097086	12/13/2017
Italy	15701577.7	1/23/2015	3097086	12/13/2017
Jersey	P1103	1/23/2015	P1103	1/8/2021
Japan	2016-548068	1/23/2015	6469711	1/25/2019
Kiribati		1/23/2015	08/2020	12/31/2020
Republic of Korea	10-2016-7022665	1/23/2015	10-2417684	7/1/2022
Cayman Islands	TBC	1/23/2015	3097086	11/13/2020
Saint Lucia		1/23/2015	PT#10 of 2020	11/10/2020
Lithuania	15701577.7	1/23/2015	3097086	12/13/2017
Luxembourg	15701577.7	1/23/2015	3097086	12/13/2017
Latvia	15701577.7	1/23/2015	3097086	12/13/2017
Monaco	15701577.7	1/23/2015	3097086	12/13/2017
Macedonia (F.Y.R.O.M)	15701577.7	1/23/2015	3097086	12/13/2017
Montserrat	3097086	1/23/2015	3097086	4/14/2021
Malta	15701577.7	1/23/2015	3097086	12/13/2017
Mexico	MX/a/2016/009349	1/23/2015	368840	10/18/2019
Malaysia	PI2016702657	1/23/2015		
Netherlands	15701577.7	1/23/2015	3097086	12/13/2017
Norway	15701577.7	1/23/2015	3097086	12/13/2017
Nauru		1/23/2015	3097086	
New Zealand	722063	1/23/2015	722063	1/4/2018
Peru	1236-2016	1/23/2015	10062	3/9/2020
Philippines	1/2016/501439	1/23/2015	1/2016/501439	3/12/2020
Poland	15701577.7	1/23/2015	3097086	12/13/2017
Portugal	15701577.7	1/23/2015	3097086	12/13/2017
Romania	15701577.7	1/23/2015	3097086	12/13/2017
Serbia	15701577.7	1/23/2015	3097086	12/13/2017
Solomon Islands	Tbc	1/23/2015	3097086	7/30/2021
Seychelles	3097086	1/23/2015	SC/P/93	11/16/2020
Sweden	15701577.7	1/23/2015	3097086	12/13/2017
Singapore	11201606052T	1/23/2015	11201606052T	1/3/2018
Saint Helena	P253	1/23/2015	253	6/21/2021
Slovenia	15701577.7	1/23/2015	3097086	12/13/2017
Slovakia	15701577.7	1/23/2015	3097086	12/13/2017
Sierra Leone	TBC	1/23/2015	3097086	
San Marino	15701577.7	1/23/2015	3097086	12/13/2017
Turks & Caicos Islands	10299	1/23/2015	3097086	11/2/2020
Thailand	1601004193	1/23/2015		
Turkey	15701577.7	1/23/2015	3097086	12/13/2017

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Tuvalu		1/23/2015	TVP 222	12/7/2020
Taiwan	104102345	1/23/2015	I690517	4/11/2020
United States of America	14/601,371	1/21/2015	9,522,894	12/20/2016
Virgin Islands (British)		1/23/2015	510/12/2020	11/12/2020
Vietnam	1-2016-02767	1/23/2015	21600	7/30/2019
South Africa	2016/05856	1/23/2015	2016/05856	2/26/2020
Albania	17195612.1	1/23/2015	3323814	5/13/2020
Austria	17195612.1	1/23/2015	3323814	5/13/2020
Australia	2017200338	1/23/2015	2017200338	6/14/2018
Belgium	17195612.1	1/23/2015	3323814	5/13/2020
Bulgaria	17195612.1	1/23/2015	3323814	5/13/2020
Switzerland	17195612.1	1/23/2015	3323814	5/13/2020
China	201910716882.4	1/23/2015		
Cyprus	17195612.1	1/23/2015	3323814	5/13/2020
Czech Republic	17195612.1	1/23/2015	3323814	5/13/2020
Germany	17195612.1	1/23/2015	3323814	5/13/2020
Denmark	17195612.1	1/23/2015	3323814	5/13/2020
Estonia	17195612.1	1/23/2015	3323814	5/13/2020
European Patent Office	17195612.1	1/23/2015	3323814	5/13/2020
Spain	17195612.1	1/23/2015	3323814	5/13/2020
Finland	17195612.1	1/23/2015	3323814	5/13/2020
France	17195612.1	1/23/2015	3323814	5/13/2020
United Kingdom	17195612.1	1/23/2015	3323814	5/13/2020
Greece	17195612.1	1/23/2015	3323814	5/13/2020
Hong Kong	18114946.6	1/23/2015	1255870	3/5/2021
Croatia	17195612.1	1/23/2015	3323814	5/13/2020
Hungary	17195612.1	1/23/2015	3323814	5/13/2020
Ireland	17195612.1	1/23/2015	3323814	5/13/2020
Israel	252836	1/23/2015	252836	7/31/2019
Iceland	17195612.1	1/23/2015	3323814	5/13/2020
Italy	17195612.1	1/23/2015	3323814	5/13/2020
Japan	2019-005300	1/23/2015	6804570	12/4/2020
Lithuania	17195612.1	1/23/2015	3323814	5/13/2020
Luxembourg	17195612.1	1/23/2015	3323814	5/13/2020
Latvia	17195612.1	1/23/2015	3323814	5/13/2020
Monaco	17195612.1	1/23/2015	3323814	5/13/2020
Macedonia (F.Y.R.O.M)	17195612.1	1/23/2015	3323814	5/13/2020
Malta	17195612.1	1/23/2015	3323814	5/13/2020
Netherlands	17195612.1	1/23/2015	3323814	5/13/2020
Norway	17195612.1	1/23/2015	3323814	5/13/2020

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
New Zealand	734768	1/23/2015		
Poland	17195612.1	1/23/2015	3323814	5/13/2020
Portugal	17195612.1	1/23/2015	3323814	5/13/2020
Romania	17195612.1	1/23/2015	3323814	5/13/2020
Serbia	17195612.1	1/23/2015	3323814	5/13/2020
Sweden	17195612.1	1/23/2015	3323814	5/13/2020
Singapore	10201701056Q	1/23/2015	10201701056Q	7/12/2019
Slovenia	17195612.1	1/23/2015	3323814	5/13/2020
Slovakia	17195612.1	1/23/2015	3323814	5/13/2020
San Marino	17195612.1	1/23/2015	3323814	5/13/2020
Turkey	17195612.1	1/23/2015	3323814	5/13/2020
United States of America	15/346,411	11/8/2016	9,815,805	11/14/2017
South Africa	2018/00431	1/23/2015	2018/00431	9/25/2019
Australia	2018202956	1/23/2015	2018202956	8/22/2019
European Patent Office	20173862.2	1/23/2015		
Hong Kong	42021030925.8	1/23/2015		
Japan	2020-200413	1/23/2015		
United States of America	15/708,634	9/19/2017	10,287,258	5/14/2019
Australia	2019202675	1/23/2015	2019202675	9/10/2020
Japan	2022-062548	1/23/2015		
United States of America	16/358,091	3/19/2019	10,669,245	6/2/2020
United States of America	16/855,522	4/22/2020	11,117,874	9/14/2021
United States of America	17/170,641	2/8/2021		
United States of America	17/942,106	9/9/2022		
United States of America	17/942,111	9/9/2022		
United States of America	17/942,112	9/10/2022		
United States of America	17/942,120	9/10/2022		
United States of America	17/942,121	9/10/2022		
United States of America	17/942,122	9/10/2022		
United States of America	17/942,123	9/10/2022		
United States of America	17/946,024	9/15/2022		
United States of America	17/946,112	9/16/2022		
INMD-133/03: COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASE AND LUNG INJURY Assignee: Insmmed Incorporated				
Australia	2018271873	11/20/2019		
Brazil	BR1120190245499	11/20/2019		
Canada	3062567	11/20/2019		
China	201880047233.3	11/20/2019		
European Patent Office	18805177.5	11/20/2019		
Israel	270686	11/20/2019		
Japan	2019-565425	11/20/2019		

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Republic of Korea	10-2019-7035481	11/20/2019		
New Zealand	758839	11/20/2019		
United Kingdom	GB1917677.5	11/20/2019		
United States of America	16/615,232	11/20/2019		
INMD-135/01: PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-((1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL)-1,4- OXAZEPANE-2-CARBOXAMIDE Assignee: AstraZeneca AB				
Australia	2019228717	3/1/2019		
Canada	3091707	3/1/2019		
China	201980028494.5	3/1/2019		
European Patent Office	19716296.9	3/1/2019		
Hong Kong	62021027740.1	3/1/2019		
Japan	2020-545547	3/1/2019		
Republic of Korea	10-2020-7028037	3/1/2019		
United States of America	16/975,292	3/1/2019		
INMD-136/00 to 01: LIPOGLYCOPEPTIDE CLEAVABLE DERIVATES AND USES THEREOF Assignee: Insmed Incorporated				
Australia	2018273887	11/20/2019		
Brazil	BR1120190244727	11/20/2019		
Canada	3062570	11/20/2019		
China	201880048300.3	11/20/2019		
European Patent Office	18805750.9	11/20/2019		
Israel	270685	11/20/2019		
Japan	2019-565468	11/20/2019		
New Zealand	758836	11/20/2019		
Republic of Korea	10-2019-7035485	7/27/2021		
United States of America	16/615,214	11/20/2019	11,071,769	7/27/2021
United States of America	17/344,322	6/10/2021		
United Kingdom	GB1917675.9	11/20/2019	2577419	8/17/2022
INMD-138/01: METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTS Assignee: Insmed Incorporated				
European Patent Office	19774338.8	3/29/2019		
Hong Kong	62021035153.7	3/29/2019		
Japan	2020-552823	3/29/2019		
United States of America	16/981,149	3/29/2019		
INMD-139/01: METHODS FOR THE MANUFACTURE OF LIPOSOMAL DRUG FORMULATIONS Assignee: Insmed Incorporated				
Australia	2019262117	5/2/2019		
Canada	3098573	5/2/2019		
China	201980042856.6	5/2/2019		
European Patent Office	19797021.3	5/2/2019		
Hong Kong	62021036765.7	5/2/2019		
Japan	2021-510282	5/2/2019		
Republic of Korea	10-2020-7034487	5/2/2019		

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
United States of America	17/052,070	5/2/2019		
INMD-141/01: CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING INFLAMMATORY BOWEL DISEASE Assignee: Insmmed Incorporated				
Australia	2019305565	7/16/2019		
Canada	3106270	7/16/2019		
Japan	2021-502436	7/16/2019		
Republic of Korea	10-2021-70004189	7/16/2019		
INMD-143/01: CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING LUPUS NEPHRITIS Assignee: Insmmed Incorporated or Insmmed, Inc.				
Australia	2019306532	7/16/2019		
Canada	3106269	7/16/2019		
Japan	2021-502574	7/16/2019		
Republic of Korea	10-2021-7004073	7/16/2019		
INMD-144/01 and INMD-145/01: LIPOGLYCOPEPTIDE CLEAVABLE DERIVATES AND USES THEREOF Assignee: Insmmed Incorporated				
European Patent Office	19888078.3	5/19/2021		
Japan	2021-526218	5/19/2021		
United States of America	17/295,370	5/19/2021		
European Patent Office	19887377	5/19/2021		
Japan	2021-526220	5/19/2021		
United States of America	17/295,360	5/19/2021		
INMD-149/01 to 02: DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF Assignee: Insmmed Incorporated				
Australia	2020265576	4/28/2020		
Brazil	1120210217754	4/28/2020		
Canada	3138530	4/28/2020		
China	202080047360.0	4/28/2020		
European Patent Office	20798330.5	4/28/2020		
Hong Kong	62022057326.0	4/28/2020		
India	202117055006	4/28/2020		
Japan	2021-564297	4/28/2020		
Republic of Korea	10-2021-7039071	4/28/2020		
Mexico	MX/a/2021/013329	4/28/2020		
United States of America	16/860,428	4/28/2020	11,458,098	10/4/2022
United States of America	17/893,991	8/23/2022		
INMD-150/01: PHARMACEUTICAL FORMULATIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2021/024077	3/25/2021		
INMD-152/02: METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATING DIPEPTIDYL PEPTIDASE 1-MEDIATED CONDITIONS Assignee: Insmmed, Inc.				
Patent Cooperation Treaty	PCT/US2021/042199	7/19/2021		
INMD-153/01: METHODS FOR TREATING NEWLY DIAGNOSED MYCOBACTERIUM AVIUM COMPLEX LUNG INFECTIONS Assignee: Insmmed Incorporated				

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Patent Cooperation Treaty	PCT/US2021/048199	8/30/2021		
INMD-154/01: DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2021/057078	10/28/2021		
INMD-155/01: CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BEHÇET'S DISEASE Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2021/064810	12/22/2021		
INMD-156/01: DRY POWDER COMPOSITIONS OF GLYCOPEPTIDE DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2022/020890	3/18/2022		
INMD-157/01: COMBINATION THERAPY FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2022/020890	3/18/2022		
INMD-158/01 to 03: CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CANCER Assignee: Insmmed Incorporated				
United States of America	63/234,961	8/19/2021		
United States of America	63/241,754	9/8/2021		
Patent Cooperation Treaty	PCT/US2022/026769	4/28/2022		
INMD-159/01: CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CYSTIC FIBROSIS Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2022/027026	4/29/2022		
INMD-160/01: IN VITRO RELEASE ASSAY METHODS FOR LIPOSOMAL AMINOGLYCOSIDE FORMULATIONS Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2022/032629	6/8/2022		
INMD-161/01: TUNABLE POLYMERIC NANOPARTICLES FOR TARGETED AND SUSTAINED DELIVERY OF GLYCOPEPTIDE ANTIBIOTICS Assignee: Insmmed Incorporated				
Patent Cooperation Treaty	PCT/US2022/040864	8/19/2022		
INMD-163/00: CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS Assignee: Insmmed, Inc.				
United States of America	63/273,540	10/29/2021		
INMD-164/00: CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVA Assignee: Insmmed Incorporated				
United States of America	63/310,751	2/16/2022		
INMD-165/01 to 03: METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE Assignee: The Research Institute at Nationwide Children's Hospital				
Australia	2015342997	11/5/2015		
Canada	2966884	11/5/2015		
Australia	2022200929	11/5/2015		
Australia	2022202738	11/5/2015		
United States of America	17/668,123	2/9/2022		
INMD-166/01 to 02: ADENO-ASSOCIATED VIRUS VECTORS AND METHODS OF USE AND DELIVERY THEREOF Assignee: Insmmed Incorporated or Insmmed, Inc.				
United States of America	63/239,881	9/1/2021		
Patent Cooperation Treaty	PCT/US2022/074622	8/5/2022		
INMD-168/01: METHODS FOR TREATING METASTASIS WITH CATHEPSIN C INHIBITORS				

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
Assignee: Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences				
Patent Cooperation Treaty	PCT/CN2021/117698	9/10/2021		
INMD-169/00: DRY POWDER COMPOSITIONS OF BEDAQUILINE AND SALTS AND METHODS OF USE THEREOF Assignee: Insmed Incorporated				
United States of America	63/307,373	2/7/2022		
INMD-170/00: RECOMBINANT AAV PARTICLES AND METHODS OF USE THEREOF Assignee: Insmed Incorporated				
United States of America	63/378,808	10/7/2022		
INMD-173/00: NOVEL DPP1 INHIBITORS AND USES THEREOF Assignee: Insmed Incorporated				
United States of America	63/369,750	7/28/2022		
INMD-180/01 to 03: THERAPEUTIC CHARGE ENGINEERED VARIANTS OF LYSOZYME AND METHODS FOR USING THE SAME TO TREAT INFECTIONS Assignee: Insmed Incorporated				
United States of America	13/144,553	1/19/2010	9,074,201	7/7/2015
United States of America	14/791,979	7/6/2015	9,950,041	4/24/2018
United States of America	15/921,365	3/14/2018		
INMD-181/02: HUMANIZED, THERMOSTABILIZED VARIANTS OF CETUXIMAB / ANTIBODIES AND METHODS OF MAKING SAME Assignee: Insmed Incorporated				
United States of America	16/303,530	5/24/2017		
China	2018780041666.3	5/24/2017		
INMD-182/01 to 04: DEIMMUNIZED LYSOSTAPHIN AND METHODS OF USE Assignee: Trustees of Dartmouth College				
Canada	2948864	5/14/2015		
China	201580038125.6	5/14/2015		
China	202011324763.3	5/14/2015		
European Patent Office	15793514.9	5/14/2015		
Japan	2017-512860	5/14/2015		
Japan	2020-109773	6/25/2020		
United States of America	15/310,917	5/14/2015	10,258,636	7/23/2019
United States of America	16/432,246	6/5/2019	11,091,749	8/17/2021
United States of America	17/199,484	3/12/2021		
INMD-183/01 to 02: UNGLOYCOSYLATED LYSOSTAPHIN VARIANT PROTEIN Assignee: Trustees of Dartmouth College				
China	.201480046809.6	7/16/2014		
Macau	J/5573	7/16/2014		
United States of America	14/907,746	7/16/2014	11,155,801	10/26/2021
United States of America	17/480,166	9/21/2021		
DEVICE FOR INHALATION THERAPY Assignee: PARI Pharma GMBH				
United States of America	10/810,098	3/26/2004	7,252,085	8/7/2007
FLUID DROPLET PRODUCTION APPARATUS AND METHOD Assignee: PARI Pharma GMBH				
United States of America	10/522,344	7/31/2003	7,931,212	4/26/2011
United States of America	13/042,980	3/8/2011	8,511,581	8/20/2013
European Patent Office	02016972.8	8/2/2002	EP1386672	3/11/2010
INHALATION THERAPY DEVICE Assignee: PARI Pharma GMBH				

Territory	Application No.	Application Date	Patent Registration No.	Registration Date
United States of America	10/533,430	10/30/2003	7,458,372	12/2/2008
European Patent Office	03809748	10/30/2003	1558315	12/30/2009
Germany	DE 10251864.5	11/7/2002	DE 10251864	6/24/2004
Germany	DE 10257381	12/9/2002	DE 10257381	4/13/2006
European Patent Office	03782349	12/9/2003	1569710	5/27/2009
United States of America	10/538,515	12/9/2003	9,061,303	6/23/2015
AEROSOL GENERATOR Assignee: PARI Pharma GMBH				
European Patent Office	12725433.2	6/4/2012	2717951	10/28/2020
United States of America	14/123,634	6/4/2012	9,975,136	5/22/2018
United States of America	15/955,973	4/18/2018	11154896	10/26/2021
United States of America	17/504,654	10/19/2021		

NY-2460130

RECORDED: 10/19/2022

PATENT
REEL: 061727 FRAME: 0070